Ovarian cancer (OC) is the most deadly gynecological malignancy worldwide. OC patients undergo debulking surgery followed by platinum/taxane-based chemotherapy; however, despite recent development of new therapeutic approaches based on combination of chemotherapy and innovative targeted-therapies, most of them relapse due to chemoresistance. Many studies have been carried out to decipher the high heterogeneity of ovarian cancer cells that drives tumor treatment failure. Here, we describe our experience in the characterization of ovarian cancer cell subsets through a high-resolution technology in multiparametric analysis, such as mass cytometry (MC).
Keywords: CyTOF; Drug resistance; Ovarian cancer; Phenotype; Single-cell mass cytometry; Tumor biomarkers.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.